gatifloxacin has been researched along with Chronic Disease in 3 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The gatifloxacin treatment resulted in significant reductions in the scores on the JPN-NIH CPSI." | 6.73 | Gatifloxacin treatment for chronic prostatitis: a prospective multicenter clinical trial. ( Hirose, T; Horita, H; Iwasawa, A; Koroku, M; Kunishima, Y; Matsukawa, M; Nishimura, M; Suzuki, N; Takahashi, S; Takeda, K; Takeyama, K; Tanaka, T; Tanda, H; Tsukamoto, T; Yokoo, A, 2008) |
| "The gatifloxacin treatment resulted in significant reductions in the scores on the JPN-NIH CPSI." | 2.73 | Gatifloxacin treatment for chronic prostatitis: a prospective multicenter clinical trial. ( Hirose, T; Horita, H; Iwasawa, A; Koroku, M; Kunishima, Y; Matsukawa, M; Nishimura, M; Suzuki, N; Takahashi, S; Takeda, K; Takeyama, K; Tanaka, T; Tanda, H; Tsukamoto, T; Yokoo, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kunishima, Y | 1 |
| Takeyama, K | 1 |
| Takahashi, S | 1 |
| Matsukawa, M | 1 |
| Koroku, M | 1 |
| Tanda, H | 1 |
| Tanaka, T | 1 |
| Hirose, T | 1 |
| Iwasawa, A | 1 |
| Nishimura, M | 1 |
| Takeda, K | 1 |
| Suzuki, N | 1 |
| Horita, H | 1 |
| Yokoo, A | 1 |
| Tsukamoto, T | 1 |
| Sato, A | 2 |
| Kitazawa, H | 2 |
| Chida, K | 2 |
| Hayakawa, H | 2 |
| Iwata, M | 2 |
1 trial available for gatifloxacin and Chronic Disease
| Article | Year |
|---|---|
Gatifloxacin treatment for chronic prostatitis: a prospective multicenter clinical trial.
Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle | 2008 |
2 other studies available for gatifloxacin and Chronic Disease
| Article | Year |
|---|---|
Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Fluoroquinolones; Gatifloxacin; Immunoglobulin A; L | 1995 |
Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Fluoroquinol | 1997 |